Showing 2751-2760 of 19323 results for "".
Introduction to Hi-Lo Phacoemulsification
https://reachmd.com/programs/cme/introduction-to-hi-lo-phacoemulsification/33178/Discover how the “Hi-Lo” phacoemulsification technique optimizes safety and efficiency in cataract surgery for routine and complex cataract cases.Primary Biliary Cholangitis: Shining Light on an "Invisible" Female Health Burden
https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/Review clinical features, diagnostic criteria, and treatment options for PBC, a chronic liver disease primarily affecting women over age 50.Establishing D-VRd Efficacy for Transplant-Ineligible Multiple Myeloma
https://reachmd.com/programs/project-oncology/establishing-d-vrd-efficacy-for-transplant-ineligible-multiple-myeloma/30049/Read about the effectiveness of adding daratumumab to the standard VRd regimen for patients with newly diagnosed multiple myeloma.Individualized Management of Hyperkalemia: The Role of Potassium Binders in Patients With Cardiorenal Disease
https://reachmd.com/clinical-practice/nephrology/individualized-management-of-hyperkalemia-the-role-of-potassium-binders-in-patients-with-cardiorenal-disease/37619/Explore practical strategies and updated guidelines to better manage hyperkalemia, maintain RASi therapy, and select potassium binders in CKD and heart failure.Integrating Palliative Care in Pulmonary Hypertension
https://reachmd.com/programs/cme/integrating-palliative-care-in-pulmonary-hypertension/33239/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.Treating Primary Biliary Cholangitis with Seladelpar: Insights from the RESPONSE Trial
https://reachmd.com/programs/gi-insights/treating-primary-biliary-cholangitis-with-seladelpar-insights-from-the-response-trial/29162/Based on the RESPONSE trial, seladelpar may be a safe and effective treatment for primary biliary cholangitis patients who don’t response to current therapies.Healthy lifestyle interventions for CVD risk reduction in secondary prevention
https://reachmd.com/cme/obesity/healthy-lifestyle-interventions-for-cvd-risk-reduction-in-secondary-prevention/17755/3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MDTargeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
https://reachmd.com/programs/medical-industry-feature/targeting-neutrophilic-inflammation-in-bronchiectasis-an-emerging-approach/33184/TBDThe Impact of Zero in Rheumatology
https://reachmd.com/programs/medical-industry-feature/the-impact-of-zero-in-rheumatology/32264/Most patients with psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis have symptoms across multiple domains.1-2 In fact, when patients meet certain outcome measures, like ACR50 or ASAS40, they may still have active disease that disrupts everyday life.3-5 And paImproving Symptoms in Patients with HFrEF Using Novel Device Therapy
https://reachmd.com/programs/cme/improving-symptoms-in-patients-with-hfref-using-novel-device-therapy/14475/Baroreflex activation therapy (BAT) provides durable and sustained benefits for exercise capacity, functional status, and QoL. Tune in to learn more!